Form 4: Haemonetics EVP Josep Llorens Reports Stock Transactions
SEC Form 4 Filing
Josep Llorens, EVP of Global Manufacturing at Haemonetics, reports the disposition and acquisition of company stock, including shares withheld for tax obligations and sales under a 10b5-1 trading plan.
Summary
- Josep Llorens, EVP of Global Manufacturing at Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
- On May 15, 2024, 258 shares were disposed of to cover tax obligations at a price of $96.49.
- On May 16, 2024, 263 shares were disposed of to cover tax obligations at a price of $94.8.
- Also on May 16, 2024, 770 shares were sold at $96.14 per share under a pre-existing 10b5-1 trading plan.
- Following these transactions, Llorens beneficially owns 17,172 shares of Haemonetics Corp.
- The transactions were executed under a 10b5-1 trading plan dated August 28, 2023, and fully executed as of August 31, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive, which are part of normal corporate activity and regulatory requirements.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. The use of 10b5-1 trading plans is a common practice to avoid accusations of insider trading, as these plans are established in advance and operate independently of any material non-public information the insider may possess.
Key Dates
| Date | Description |
|---|---|
| August 28, 2023 | Date of the 10b5-1 trading plan |
| August 31, 2023 | Date the 10b5-1 trading plan was fully executed |
| 05/15/2024 | Date of the first reported transaction (disposal of shares for tax obligations) |
| 05/16/2024 | Date of the second and third reported transactions (disposal of shares for tax obligations and sale under 10b5-1 plan) |
| 05/17/2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.